Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Míreanna comhchosúla

• Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
  de réir: Sheheryar Kabraji (15050565)
  Foilsithe / Cruthaithe: (2025)
• Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
  de réir: Nigel Bundred (15046233)
  Foilsithe / Cruthaithe: (2025)
• Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
  de réir: Nigel Bundred (15046233)
  Foilsithe / Cruthaithe: (2025)
• Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
  de réir: Nigel Bundred (15046233)
  Foilsithe / Cruthaithe: (2025)
• Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer
  de réir: Jamunarani Veeraraghavan (16461809)
  Foilsithe / Cruthaithe: (2025)